Monitor the Fireside Chat webcast on August 11 for any non-public commentary on the Phase III MAVERIC trial timeline or CRD-38 development progress. This filing alone provides no trading signal.
Price Chart
Executive Summary
Cardiol Therapeutics filed a 6-K announcing its participation in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference on August 11, 2026. The filing contains no material financial, clinical, or corporate updates—it is a routine investor conference participation notice.
Key Facts
- Cardiol will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference on August 11, 2026 at 9:00 a.m. EDT in Boston, MA.
- The company's lead drug candidate is CardiolRx, with an ongoing pivotal Phase III MAVERIC trial in recurrent pericarditis.
- No financial results, guidance, clinical data, or regulatory updates were disclosed in this filing.
Financial Impact
No material financial information disclosed; conference participation is routine and has no quantifiable financial impact.
Risk Factors
- As a pre-commercial biotech, Cardiol is exposed to clinical trial risk, regulatory risk, and capital market dependency—none of which are addressed by this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001279569-26-000745 |
| Document: cardiol6k.htm | 0001279569-26-000745 |
| Document: 0001279569-26-000745-index-headers.html | 0001279569-26-000745 |
| Document: 0001279569-26-000745-index.html | 0001279569-26-000745 |
| Document: 0001279569-26-000745.txt | 0001279569-26-000745 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | SC 13G/A | $1.77 | awaiting T+60 | — | $1.12 (−36.72%) |
Sep 23, 2026 4w ago | 6-K | $1.77 | awaiting T+60 | — | $1.12 (−36.72%) |
Sep 16, 2026 5w ago | 6-K | $1.90 | awaiting T+60 | — | $1.12 (−41.05%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.12 (−43.86%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.12 (−43.86%) |
Sep 9, 2026 6w ago | 6-K | $2.29 | awaiting T+60 | — | $1.12 (−50.98%) |
Aug 5, 2026 11w ago | 6-K | $1.34 | awaiting T+60 | — | $1.12 (−16.42%) |
Jul 14, 2026 15w ago | 6-K | $1.15 $1.32 | ▲ +14.78% | ▲ +11.41% | $1.12 (−2.61%) |
Jul 9, 2026 15w ago | 6-K | $0.9920 $1.41 | ▲ +42.14% | ▲ +40.50% | $1.12 (+12.90%) |
May 26, 2026 21w ago | 6-K | $1.30 $1.96 | ▲ +50.77% | ▲ +48.04% | $1.12 (−13.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers